Hatata Tomoko, Takaya Seigo, Taniguchi Kenjiro, Naka Takuji, Kondo Akira, Ikeguchi Masahide
Dept. of Surgery, Graduate School of Medicine, Tottori University, Japan.
Gan To Kagaku Ryoho. 2011 Jan;38(1):109-12.
A 75-year-old man with pancreatic body cancer underwent distal pancreatectomy and was treated with gemcitabine (GEM) as an adjuvant therapy. Multiple liver metastases appeared three months after the surgery. With GEM+S-1 combined chemotherapy, liver metastatic lesions became unidentifiable upon imaging 7 months later. Complete response status had continued as long as 13 months. Though grade 3 neutropenia appeared after 2 courses of the combined therapy, the patient well tolerated it after controlling the dosing schedule. The GEM+S-1 combined chemotherapy was expected to have synergistic effects for GEM monotherapy-refractive pancreatic cancer.
一名75岁的胰体癌男性患者接受了胰体尾切除术，并接受吉西他滨（GEM）辅助治疗。术后三个月出现多发肝转移。采用GEM+S-1联合化疗后，7个月后影像学检查显示肝转移灶消失。完全缓解状态持续了13个月。虽然联合治疗2个疗程后出现3级中性粒细胞减少，但通过调整给药方案，患者耐受性良好。GEM+S-1联合化疗有望对GEM单药难治性胰腺癌产生协同作用。
